Related references
Note: Only part of the references are listed.Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study
Niklas Schmedt et al.
DIABETES OBESITY & METABOLISM (2019)
Fracture Risk After Initiation of Use of Canagliflozin A Cohort Study
Michael Fralick et al.
ANNALS OF INTERNAL MEDICINE (2019)
Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis
Hao Wang et al.
BMJ OPEN (2019)
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Yan Zheng et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study
Wen-Hsuan Hou et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Initiation of dapagliflozin and treatment-emergent fractures
Konstantinos A. Toulis et al.
DIABETES OBESITY & METABOLISM (2018)
The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study
John-Michael Gamble et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study
E. Losada et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
Shih-Yi Lin et al.
FRONTIERS IN PHARMACOLOGY (2018)
Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
Y. S. Zhang et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials
Md Azharuddin et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Peter Ueda et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study
Jenny E. Blau et al.
JCI INSIGHT (2018)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock et al.
DIABETES OBESITY & METABOLISM (2018)
The use of incretins and fractures - a meta-analysis on population-based real life data
Johanna H. M. Driessen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
Robert G. Josse et al.
DIABETES OBESITY & METABOLISM (2017)
Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly: A Study From the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO)
Marit Wallander et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Mechanisms of diabetes mellitus-induced bone fragility
Nicola Napoli et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data
S. Dombrowski et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.
K. Kostev et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?
J. H. M. Driessen et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Mohammad Adil et al.
PHARMACOLOGICAL REPORTS (2017)
Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial
Andre Gustavo Daher Vianna et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study
Christian Bommer et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials
Jun Yang et al.
PLOS ONE (2017)
Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis
Eladio Losada-Grande et al.
SCIENTIFIC REPORTS (2017)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
Darin Ruanpeng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Diabetes, bone and glucose-lowering agents: clinical outcomes
Ann V. Schwartz
DIABETOLOGIA (2017)
Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study
Johanna H. M. Driessen et al.
DIABETES OBESITY & METABOLISM (2017)
Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes
Jakob Starup-Linde et al.
BONE (2017)
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
H. L. Tang et al.
DIABETES OBESITY & METABOLISM (2016)
DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis
Jil Mamza et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES
Matthew P. Gilbert et al.
ENDOCRINE PRACTICE (2016)
Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study
Sumit R. Majumdar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants
Bin Zhou et al.
LANCET (2016)
Risk of fractures and diabetes medications: a nationwide cohort study
H. J. Choi et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
Jianying Fu et al.
SCIENTIFIC REPORTS (2016)
Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes
Renyuan Li et al.
ACTA DIABETOLOGICA (2015)
Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
Johanna H. M. Driessen et al.
CALCIFIED TISSUE INTERNATIONAL (2015)
Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
Johanna H. M. Driessen et al.
CALCIFIED TISSUE INTERNATIONAL (2015)
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon et al.
DIABETES CARE (2015)
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
B. Bode et al.
DIABETES OBESITY & METABOLISM (2015)
Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs
Johanna H. M. Driessen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2015)
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials
Bin Su et al.
ENDOCRINE (2015)
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhong-Ning Zhu et al.
BONE (2014)
Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
Johanna H. M. Driessen et al.
BONE (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials
Guillaume Mabilleau et al.
JOURNAL OF DIABETES (2014)
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment
Goodarz Danaei et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
O. Ljunggren et al.
DIABETES OBESITY & METABOLISM (2012)
Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients
Mathijs C. Bunck et al.
JOURNAL OF DIABETES (2012)
Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES CARE (2011)
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
M. C. Bunck et al.
DIABETES OBESITY & METABOLISM (2011)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture
Mohsen Janghorbani et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
S Duval et al.
BIOMETRICS (2000)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
